{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:28:02Z","timestamp":1782278882554,"version":"3.54.5"},"reference-count":21,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,5,6]],"date-time":"2008-05-06T00:00:00Z","timestamp":1210032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Objective\u2003<\/jats:bold> Despite the widespread medical use of glucocorticoids, reports of factitious administration of these hormones have been uncommon. We herein report an outbreak of Cushing's syndrome in Tehran among the addicts using Tamgesic (a brand of Buprenorphine) to help them through the narcotic withdrawal stage, without knowledge of the glucocorticoid content of the black\u2010market drug.<\/jats:p><jats:p><jats:bold>Design and measurements\u2003<\/jats:bold> Case histories of 19 patients with a final diagnosis of iatrogenic Cushing's syndrome were reviewed. Liquid chromatography\/mass spectrometry (LC\u2013Mass) method was used to evaluate glucocorticoid existence in the brand. High performance liquid chromatography was used to determine plasma dexamethasone level.<\/jats:p><jats:p><jats:bold>Results\u2003<\/jats:bold> No buprenorphine was present in the vials. Each Tamgesic vial contained 0\u00b74\u00a0mg of Dexamethasone disodium phosphate; Heroin was also found in them. The duration of injection abuse and the total dexamethasone intake was 4\u00b75 (1\u201318) months and 2\u00b76 (0\u00b78\u20138)\u00a0mg\/day, respectively. Median plasma dexamethasone concentration was 5\u00b78\u00a0nmol\/l, with a range of 5\u20138\u00b77. Physical findings of the cases were not different from those of the classic endogenous Cushing's syndrome but their serum cortisol and urinary free cortisol were suppressed. Severe life\u2010threatening complications were demonstrated in five cases.<\/jats:p><jats:p><jats:bold>Conclusion\u2003<\/jats:bold> Surreptitious use of steroids resulting in Cushing's syndrome may be more common in opium addicts; a high degree of suspicion is needed to uncover this disorder. Whenever facing a cushingoid appearance in addicts, the possibility of using black market drugs with corticosteroid contents should be kept in mind.<\/jats:p>","DOI":"10.1111\/j.1365-2265.2008.03290.x","type":"journal-article","created":{"date-parts":[[2008,5,6]],"date-time":"2008-05-06T07:44:01Z","timestamp":1210059841000},"page":"921-925","source":"Crossref","is-referenced-by-count":14,"title":["Outbreak of exogenous Cushing's syndrome due to unlicensed medications"],"prefix":"10.1111","volume":"69","author":[{"given":"Fereidoun","family":"Azizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Jahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hedayati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Lankarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi Shahrad","family":"Bejestani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Esfahanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nargues","family":"Beyraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Noroozi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzad","family":"Kobarfard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,11,12]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"377","volume-title":"Anti\u2010Inflammatory Steroid Action Basic and Clinical Aspects","author":"Axelrod L.","year":"1989"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.10.3573"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5858.93"},{"key":"e_1_2_6_5_2","first-page":"852","article-title":"Prednisone\u2013induced Munchausen syndrome","volume":"135","author":"Witt M.E.","year":"1981","journal-title":"American Journal of Disease Child"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-61-2-385"},{"key":"e_1_2_6_7_2","first-page":"165","article-title":"Factitious Cushing's syndrome","volume":"111","author":"O\u2019Hare J.P.O.","year":"1986","journal-title":"Acta Endocrinologica (Copenhagen)"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.10.3050"},{"key":"e_1_2_6_9_2","first-page":"181","article-title":"Self\u2010induced Cushing's syndrome due to dexamethasone abuse in nasal spray: clinical and biochemical study","volume":"11","author":"Sastre J.","year":"1994","journal-title":"Anales de Medicina Interna"},{"key":"e_1_2_6_10_2","first-page":"77","article-title":"Cushing's syndrome from topical glucocorticoids","volume":"42","author":"Teelucksingh S.","year":"1993","journal-title":"West Indian Medical Journal"},{"key":"e_1_2_6_11_2","first-page":"250","article-title":"Uses, adverse effects of abuse of glucocorticoids","volume":"22","author":"Imam A.P.","year":"1994","journal-title":"Allergologia et Immunopathologia (Madr)"},{"key":"e_1_2_6_12_2","first-page":"908","article-title":"HPLC determination of dexamethasone in human plasma and its application to an in vitro release study from endovascular stents","volume":"61","author":"Kumar V.","year":"2006","journal-title":"Pharmazie"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(51)92313-6"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-108-2-252"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198208123070705"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.266.11.1553"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.3.294"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.1.151"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2004.033605"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.20.3045"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710303371807"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra020529"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2008.03290.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2008.03290.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:53:29Z","timestamp":1697234009000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2008.03290.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,12]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["10.1111\/j.1365-2265.2008.03290.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03290.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,12]]}}}